[The role of Stratus OCT in anti-VEGF therapy. Qualitative and quantitative assessment of neovascular AMD].
BACKGROUND
The evaluation of OCT3 during anti-VEGF therapy.


METHODS
A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months.


RESULTS
The central retinal thickness (CRT) was assessed correctly by OCT in 128 out of 145 measurements. There was a distinct (84%) but not significant correlation between decrease in central retinal thickness and increase in visual acuity. Incorrect retinal layer segmentation and inadequate CRT measurements were a significant technical limitation.


CONCLUSIONS
During anti-VEGF therapy, OCT allows documentation and quantification of morphologic retinal changes and in most cases also for an estimation of functional improvement.
Bolz
M
M
Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Osterreich.
Ritter
M
M
Polak
K
K
Ahlers
C
C
Hirn
C
C
Prünte
C
C
Golbaz
I
I
Benesch
T
T
Schmidt-Erfurth
U
U
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D016510:Corneal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008268:Macular Degeneration / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*
D000911:Antibodies, Monoclonal; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A